Literature DB >> 1340506

Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers.

L Ottonello1, P Dapino, G Pastorino, F Dallegri.   

Abstract

The superoxide (O2) production by phagocytes (neutrophils plus monocytes) and the lactoferrin release by neutrophils were measured in normal volunteers before and after the oral administration of the anti-inflammatory drug nimesulide. The chemotactic factor N-formylmethionyl-leucyl-phenylalanine (FMLP) and opsonized zymosan particles (OPZ) were used as activating stimuli. The oral administration of nimesulide lowered the phagocyte ability to generate O2- in response to both FMLP (percent inhibition = 67.62) and OPZ (percent inhibition = 36.75). The lactoferrin release by neutrophils was unaffected, proving that the drug does not affect the exocytosis of specific granules. The results provide direct evidence that the oral administration of nimesulide efficiently reduces the oxidative potential of phagocytes, particularly neutrophils, without interfering with mechanisms related to exocytosis of specific granules and involved in the amplification of the cell responses to inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1340506

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  3 in total

Review 1.  The importance of COX-2 inhibition for aspirin induced asthma.

Authors:  A Bennett
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Nimesulide as a downregulator of the activity of the neutrophil myeloperoxidase pathway. Focus on the histoprotective potential of the drug during inflammatory processes.

Authors:  L Ottonello; P Dapino; G Pastorino; G Montagnani; F Gatti; G Guidi; F Dallegri
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Are there any differences among non-steroidal anti-inflammatory drugs? Focus on nimesulide.

Authors:  Franco Dallegri; Luciano Ottonello
Journal:  Clin Drug Investig       Date:  2007-12       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.